MeSH term
Frequency | Condition_Probility | Female | 36 | 0.0 |
Humans | 151 | 0.0 |
Pregnancy | 6 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
*Adenosinetriphosphatase | 2 | 2.0 |
Alleles | 3 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Base Sequence | 9 | 0.0 |
DNA Primers | 3 | 0.0 |
Epithelial Cells/microbiology | 2 | 8.0 |
*Fimbriae, Bacterial | 2 | 40.0 |
Gene Expression | 2 | 0.0 |
*Molecular Motors | 2 | 13.0 |
Molecular Sequence Data | 8 | 0.0 |
Mutagenesis | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 42 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Adult | 24 | 0.0 |
Calcium/*metabolism | 9 | 1.0 |
Calmodulin/*metabolism | 4 | 8.0 |
Child | 10 | 0.0 |
Child, Preschool | 7 | 0.0 |
Middle Aged | 18 | 0.0 |
Male | 39 | 0.0 |
3-Hydroxyacyl CoA Dehydrogenases/*deficiency | 2 | 100.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Infant | 7 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Time Factors | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 88 | 0.0 |
Trifluoperazine/*pharmacology | 36 | 94.0 |
Calmodulin/metabolism | 4 | 9.0 |
Cells, Cultured | 18 | 0.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Drug Interactions | 3 | 0.0 |
Erythrocytes/*drug effects | 2 | 9.0 |
Trifluoperazine/*toxicity | 2 | 100.0 |
Blotting, Western | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Animals | 38 | 0.0 |
Calmodulin/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Chlorpromazine/pharmacology | 5 | 19.0 |
Dopamine Antagonists/*pharmacology | 3 | 30.0 |
Mice | 8 | 0.0 |
Sulfonamides/pharmacology | 11 | 10.0 |
Trifluoperazine/pharmacology | 35 | 68.0 |
Genotype | 4 | 0.0 |
Multienzyme Complexes/*deficiency/genetics | 3 | 100.0 |
Rats | 19 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Rats, Wistar | 9 | 0.0 |
Vanadates/pharmacology | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Calcium/metabolism | 9 | 0.0 |
Calcium Channel Blockers/pharmacology | 5 | 5.0 |
Calcium Chloride/pharmacology | 3 | 14.0 |
Clone Cells | 2 | 0.0 |
Calmodulin/*antagonists & inhibitors | 18 | 78.0 |
Binding Sites | 5 | 0.0 |
Blood | 2 | 1.0 |
Calcium-Binding Proteins/*genetics | 2 | 2.0 |
Liver/*metabolism | 2 | 0.0 |
Phosphorylation | 7 | 0.0 |
Protein Binding | 2 | 0.0 |
Comparative Study | 19 | 0.0 |
In Vitro | 12 | 0.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Phenotype | 5 | 0.0 |
Aged | 7 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Blood Platelets/drug effects/*metabolism | 2 | 2.0 |
Calcimycin/pharmacology | 6 | 2.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Phagocytosis | 3 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Prospective Studies | 4 | 0.0 |
3-Hydroxyacyl CoA Dehydrogenases/*deficiency/genetics | 2 | 66.0 |
Heterozygote | 2 | 0.0 |
Multienzyme Complexes/*deficiency/*genetics | 2 | 66.0 |
Alprostadil/*pharmacology | 2 | 18.0 |
Calcium/analysis | 2 | 6.0 |
*Kidney Transplantation | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Bacterial Proteins/*genetics | 2 | 3.0 |
Immunoblotting | 2 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
*Transferases | 2 | 5.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Thrombin/pharmacology | 2 | 0.0 |
Egtazic Acid/pharmacology | 8 | 7.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Estrogen Antagonists/*pharmacology | 2 | 2.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Verapamil/pharmacology | 3 | 3.0 |
Calmodulin/antagonists & inhibitors/*physiology | 3 | 60.0 |
Enzyme Activation | 4 | 0.0 |
Sulfonamides/*pharmacology | 5 | 11.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Adolescent | 8 | 0.0 |
Exons | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Fluorescence | 2 | 0.0 |
Cell Line | 10 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Antipsychotic Agents/*pharmacology | 3 | 12.0 |
Drug Therapy, Combination | 2 | 0.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
Calcium/pharmacology | 6 | 2.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Reference Standards | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Calcium/*physiology | 3 | 2.0 |
Calmodulin/*physiology | 3 | 27.0 |
Drug Resistance | 4 | 0.0 |
Mutation | 6 | 0.0 |
DNA/genetics | 2 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Deafness/genetics | 2 | 4.0 |
Diagnosis, Differential | 3 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Inclusion Bodies/pathology | 2 | 9.0 |
Leukocytes/pathology | 2 | 6.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Models, Molecular | 3 | 0.0 |
Molecular Motors/chemistry/*genetics | 2 | 33.0 |
Myosin Heavy Chains/*blood/chemistry/*genetics | 2 | 33.0 |
Neutrophils/*metabolism/pathology | 2 | 20.0 |
Protein Conformation | 2 | 0.0 |
Thrombocytopenia/*blood/diagnosis/*genetics | 2 | 33.0 |
*Platelet Aggregation/drug effects | 2 | 6.0 |
Age Factors | 2 | 0.0 |
Questionnaires | 2 | 0.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Drug Synergism | 6 | 0.0 |
Free Radical Scavengers | 2 | 8.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
English Abstract | 9 | 0.0 |
Lung Neoplasms/*pathology | 2 | 2.0 |
Tumor Cells, Cultured/drug effects | 6 | 1.0 |
Tritium | 2 | 0.0 |
Kidney Cortex/*metabolism | 2 | 28.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Cell Survival/drug effects | 5 | 0.0 |
Calmodulin/antagonists & inhibitors/*metabolism | 3 | 50.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Second Messenger Systems | 2 | 2.0 |
Calmodulin/antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Egtazic Acid/analogs & derivatives/pharmacology | 2 | 7.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Kinetics | 12 | 0.0 |
Temperature | 3 | 0.0 |
Gerbillinae | 2 | 5.0 |
Retrospective Studies | 2 | 0.0 |
Biological Transport, Active | 2 | 1.0 |
Rats, Inbred Strains | 4 | 0.0 |
Embryo | 2 | 0.0 |
Lung/cytology | 2 | 3.0 |
Calmodulin/antagonists & inhibitors/metabolism | 2 | 50.0 |
Pertussis Toxin | 2 | 1.0 |
Phosphatidylinositols/metabolism | 2 | 1.0 |
Receptors, IgG | 3 | 2.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Molecular Weight | 3 | 0.0 |
Parainfluenza Virus 1, Human/immunology | 2 | 66.0 |
Calcium/physiology | 3 | 1.0 |
Immunohistochemistry | 2 | 0.0 |
Swine | 2 | 0.0 |
Arachidonic Acid | 3 | 4.0 |
Arachidonic Acids/blood | 2 | 18.0 |
Blood Platelets/*drug effects/metabolism | 2 | 5.0 |
Fetus | 2 | 0.0 |
Calmodulin/physiology | 2 | 13.0 |
Histamine Release/*drug effects | 3 | 10.0 |
Neutrophils/drug effects/*secretion | 2 | 66.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Chlorpromazine/*pharmacology | 2 | 9.0 |
Imidazoles/*pharmacology | 3 | 4.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Perfusion | 2 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Drug Evaluation | 2 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Myosins/*metabolism | 3 | 15.0 |
Receptor, Insulin/*metabolism | 2 | 3.0 |
Calmodulin/antagonists & inhibitors | 4 | 20.0 |
Gallic Acid/*analogs & derivatives/pharmacology | 2 | 50.0 |
Guinea Pigs | 2 | 0.0 |
Arachidonic Acids/*blood | 2 | 22.0 |
Superoxides/metabolism | 2 | 0.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
*Benzylisoquinolines | 2 | 18.0 |
Phenothiazines/pharmacology | 2 | 28.0 |
Amiloride/pharmacology | 2 | 5.0 |
Gallic Acid/analogs & derivatives/pharmacology | 4 | 25.0 |
Cations, Divalent/pharmacology | 2 | 5.0 |
Cytochalasin B/pharmacology | 3 | 3.0 |
Deoxyglucose/pharmacology | 2 | 10.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Neutrophils/*enzymology | 2 | 1.0 |
Calmodulin/metabolism/physiology | 2 | 66.0 |
Culture Media | 2 | 0.0 |
Fibroblasts | 2 | 0.0 |
Animals, Genetically Modified | 3 | 1.0 |
Exocytosis/drug effects | 2 | 9.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Endocytosis/*drug effects | 2 | 9.0 |
Calcium-Binding Proteins/*antagonists & inhibitors | 3 | 100.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
